NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 180 filers reported holding NEKTAR THERAPEUTICS in Q2 2016. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $796,000 | -49.7% | 39,828 | -41.7% | 0.07% | -58.6% |
| Q2 2020 | $1,582,000 | +671.7% | 68,345 | +493.1% | 0.16% | +636.4% |
| Q1 2020 | $205,000 | -78.8% | 11,524 | -60.0% | 0.02% | -60.7% |
| Q1 2019 | $967,000 | -9.1% | 28,800 | -11.1% | 0.06% | +1.8% |
| Q4 2018 | $1,064,000 | -7.6% | 32,400 | +71.4% | 0.06% | +37.5% |
| Q3 2018 | $1,152,000 | -88.8% | 18,900 | -91.1% | 0.04% | -81.2% |
| Q2 2018 | $10,312,000 | +768.7% | 211,200 | +205.6% | 0.21% | +446.2% |
| Q3 2016 | $1,187,000 | +42.8% | 69,100 | +18.3% | 0.04% | 0.0% |
| Q2 2016 | $831,000 | +193.6% | 58,400 | +247.6% | 0.04% | +129.4% |
| Q4 2015 | $283,000 | -39.7% | 16,800 | -60.7% | 0.02% | -51.4% |
| Q3 2015 | $469,000 | -6.2% | 42,800 | +7.0% | 0.04% | -53.3% |
| Q2 2015 | $500,000 | +228.9% | 40,000 | +236.1% | 0.08% | +177.8% |
| Q2 2014 | $152,000 | +46.2% | 11,900 | +19.0% | 0.03% | +200.0% |
| Q3 2013 | $104,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |